To realize Agenda 2030, aid agencies, private philanthropies, and their partners in the Global South need better data to monitor how official development finance (ODF) dollars advance the Sustainable Development Goals (SDGs) and avoid missing the mark. In this report, we summarize the results of a n...ovel effort to tag and analyze 2.7 million ODF projects between 2010-2021 using machine learning to understand their contributions to the SDG thematic areas at a goal
and target level. This time frame is instructive: it compares the last six years of the Millennium Development Goals era and the first six years of the new SDG age, from early optimism to later uncertainty about the resilience of the agenda to drive collective commitments amid unanticipated global shocks.
more
Insufficient funding is hindering the achievement of malaria elimination targets in Africa, despite the pressing need for increased investment in malaria control. While Western donors attribute their inaction to financial constraints, the global health community has limited knowledge of China’s ex...panding role in malaria prevention. This knowledge gap arises from the fact that China does not consistently report its foreign development assistance activities to established aid transparency initiatives. Our work focuses on identifying Chinese-funded malaria control projects throughout Africa and linking them to official data on malaria prevalence. By doing so, we aim to shed light on China’s contributions to malaria control efforts, analysing their investments and assessing their impact. This would provide valuable insights into the development of effective financing mechanisms for future malaria control in Africa.
more
Rising levels of inflation, debt and macrofiscal tightening are putting expenditures on the social sectors including health under immense scrutiny. Already, there are worrying signs of reductions in social sector investments. However, even before the pandemic, evidence showed the significant returns... on investments in health equity and its social determinants. Emerging data and trends show that these potential returns have increased during the COVID-19 pandemic - investments in social determinants can mitigate widespread reductions in human capital and the increasing likelihood of costly syndemics, while promoting access to healthcare innovations that have thus far been inequitably distributed. Therefore, we argue that, despite immediate fiscal pressures, this is exactly the time to invest in health equity and its broader social determinants, as the returns on such investments have never been greater.
more
Development finance is at a turning point, as the macroeconomic environment has changed profoundly and the financing gap for low- and middle-income countries has widened. The events that led to this new situation are the multiple crises that the global economy is facing, such as the climate crisis, ...the COVID-19 crisis and the war in Ukraine. As a
result, interest rates have risen sharply over the past year and are not expected to decline anytime soon. High interest rates further restrict low- and middle-income countries’ access to international financial markets by making borrowing more expensive. At the same time, debt
levels in several countries are rising to levels that are almost impossible to repay. Poorer countries find themselves in a trap where financing the Sustainable Development Goals (SDGs) becomes a distant goal for them.
more
For this report, the Task Force commissioned
additional background papers on health taxes to
update the evidence, assess short-term revenue
potential, and understand the role of health taxes
in the current era of multiple crises. We find that
health taxes continue to be underutilized despite th...e
powerful impact they have in reducing preventable
death and disease — a particularly glaring act of
neglect in a world that has experienced a massive
pandemic.
more
The UK could regain its leadershipin the provision of development assistance for healthunder the next government. But this doesn’t seem likely if the party manifestos are any guide.
Translation provided of the German Asylum Procedure Act (Asylverfahrensgesetz) by the Language Service of the Federal Ministry of the Interior. The translation includes the amendment(s) to the Act by Article 2 of the Act of
23.12.2014 (Federal Law Gazette I p. 2439). BEWARE: This version does no...t include the amendment of Nov. 2011! To compare with the current status of the German version, see http://www.gesetze-im-internet.de/asylvfg_1992/BJNR111260992.html.
more
Initiation à la Méthodologie de la recherche en Santé, Guide de Formateur
Der BAGSO-Ratgeber informiert kompakt und verständlich zu Impfungen für Erwachsene ab 60 Jahren. Er gibt Antworten auf zwölf häufig gestellte Fragen, u.a. für wen welche Impfungen besonders wichtig sind, wo man sich beraten lassen kann und ob die Kosten von der Krankenkasse übernommen werden. ...Ein Adressteil benennt Ansprechpartner, die bei Bedarf weiterführende Informationen anbieten.
more
Female Genital Mutilation (weibliche Genitalverstümmelung, FGM) ist ein globales Problem. Weltweit sind mehr als 200 Millionen Frauen und Mädchen betroffen. Davon lebten im Jahr 2020 ca. 75.000 in Deutschland. Viele der Betroffenen leiden unter FGM-bedingten Beschwerden
und benötigen medizinisch...e Hilfe. Leider gibt es in Deutschland bisher nur wenige medizinische Anlaufstellen, die qualitativ hochwertige und evidenzbasierte Versorgung für die Betroffenen gewährleisten. In Bayern leben schätzungsweise 13.000 Frauen mit Genitalverstümmelung. Im
Münchner Universitätsklinikum rechts der Isar gibt es bayernweit die erste medizinische Sprechstunde für von FGM betroffene Frauen und Mädchen.
more
Bebilderte Informationsblätter in Deutsch-Englisch-Französisch-Polnisch-Russisch-Serbisch-
Albanisch-Türkisch-Arabisch-Farsi-Urdu
This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were i...ncluded. A total of 1089 patients were analyzed, of whom 65.3% had only IHD, 17.8% PAD and 16.9% both. A total of 80.6% were taking only one antiplatelet agent, and 18.2% were on dual antiplatelet therapy (mainly aspirin/clopidogrel). Almost all patients were taking ≥1 lipid lowering drug, mainly moderate-to-high intensity statins. IHD patients took ezetimibe more commonly than PAD (43.9% vs. 12.9%; p < 0.001). There were more patients with IHD that achieved blood pressure targets compared to PAD (<140/90 mmHg: 67.9% vs. 43.0%; p < 0.001; <130/80 mmHg: 34.1% vs. 15.7%; p < 0.001), LDL-cholesterol (<70 mg/dL: 53.1% vs. 41.5%; p = 0.033; <55 mg/dL: 26.5% vs. 16.0%; p = 0.025), and diabetes (HbA1c < 7%, with SGLT2i/GLP1-RA: 21.7% vs. 8.8%; p = 0.032). Modifications of antihypertensive agents and lipid-lowering therapy were performed in 69.0% and 82.3% of patients, respectively, without significant differences between groups. The use of SGLT2i/GLP1-RA was low. In conclusion, cardiovascular risk factors control remains poor among patients with IHD, PAD, or both. A higher use of combined therapy is warranted.
more
Nutrition data and information systems (ND&IS) are critical to guide the prioritisation, collection, analysis and
dissemination of nutrition data in countries. However, there is limited guidance for countries regarding how to invest
in their ND&IS and little is known about current financing alloca...tions by both countries and donors
more
This online learning course is for primary care of children witt TB. It covers clinical presentation, diagnosis, management and prevention of tb in children and HIV/TB co-infection
To meet the need for laboratory diagnosis to be integrated in community care, the new 2022 Update describes point-of-care tests that can be performed both in district laboratories and peripheral healthcare facilities by non-specialist staff. Also included are recently developed self-tests.
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58